Coincident with the aforementioned findings, Laptm5 overexpression greatly mitigated inflammation, fibrosis, and hepatic injury during NASH progression (Supplementary Fig. 7j–p). This evidence concerns the gene LAPTM5 and metabolic dysfunction-associated steatohepatitis.